Literature DB >> 25818022

Reduction in the prevalence of carbapenem-resistant Acinetobacter baumannii and Pseudomonas aeruginosa in New York City.

Marie Abdallah1, Olawole Olafisoye1, Christopher Cortes2, Carl Urban2, Clayton Charles1, David Landman1, John Quale3.   

Abstract

We compared susceptibilities of Acinetobacter baumannii and Pseudomonas aeruginosa collected during surveillance studies conducted during 2009 and 2013-2014 involving hospitals in New York City. There were significant decreases in the number of carbapenem-resistant A baumannii and P aeruginosa cases during 2013-2014; it appears the institution of effective infection control measures has contributed to this decline. However the number of isolates of A baumannii with OXA-23-type β-lactamase increased during 2013-2014.
Copyright © 2015 Association for Professionals in Infection Control and Epidemiology, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Carbapenemases; Multidrug resistance; Nosocomial pathogens

Mesh:

Substances:

Year:  2015        PMID: 25818022     DOI: 10.1016/j.ajic.2015.02.018

Source DB:  PubMed          Journal:  Am J Infect Control        ISSN: 0196-6553            Impact factor:   2.918


  3 in total

1.  Activity of Meropenem with a Novel Broader-Spectrum β-Lactamase Inhibitor, WCK 4234, against Gram-Negative Pathogens Endemic to New York City.

Authors:  Alejandro Iregui; Zeb Khan; David Landman; John Quale
Journal:  Antimicrob Agents Chemother       Date:  2019-12-20       Impact factor: 5.191

2.  Activity of Cefiderocol Against Enterobacterales, Pseudomonas aeruginosa, and Acinetobacter baumannii Endemic to Medical Centers in New York City.

Authors:  Alejandro Iregui; Zeb Khan; David Landman; John Quale
Journal:  Microb Drug Resist       Date:  2020-02-07       Impact factor: 3.431

3.  Epidemiological evaluation of an Acinetobacter baumannii outbreak observed at an intensive care unit.

Authors:  Tuğba K Atik; Bülent Atik; Osman Kilinç; Bayhan Bektöre; Hülya Duran; Burak M Selek; Nihan Ceken; Orhan Baylan; Mustafa Özyurt
Journal:  Saudi Med J       Date:  2018-08       Impact factor: 1.484

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.